Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more immune checkpoint inhibitor (ICI) therapy

Read more at globenewswire.com